The Morane-Saulnier L, or Morane-Saulnier Type L, or MoS-3, was a French parasol wing one or two-seat scout aeroplane of the First World War. The Type L became one of the first successful fighter aircraft when it was fitted with a single machine gun that fired through the arc of the propeller, protected by armoured deflector wedges, its immediate effectiveness in this role launched an arms race in fighter development, the Type L was swiftly rendered obsolete. The original Type L used wing warping for lateral control, but a version designated Type LA was fitted with ailerons. Built by Morane-Saulnier, large numbers of the Type L were ordered by the French Aviation Militaire at the outbreak of the war. In total about 600 Type Ls were built and, in addition to the French air force, they served with the Royal Flying Corps, Royal Naval Air Service and the Imperial Russian Air Service; the type was produced under licence in Germany by Pfalz Flugzeugwerke as the unarmed A. I and A. II scouts. About 60 were built for Bavarian air service.
A few were modified as the E. III fighters. A few Type Ls captured by Germany were fitted with a single German Spandau LMG 08 machine gun; these captured and converted aircraft are mistaken for Pfalz E. IIIs. About 450 aircraft were licence-built in Russia by Lebed works; the Morane-Saulnier L was built under licence in Sweden with some minor improvements as the Thulin D. In December 1914 the famous French aviator Roland Garros serving with Escadrille 23, worked with Raymond Saulnier to create a gun synchronizer, using the gas operated Hotchkiss light machine gun; however the firing rate fluctuated too much for the synchronizer to function properly. As an interim measure, they designed a "safety backup" in the form of braced "deflectors" fitted to the rear surfaces of the propeller blades at the points where they could be struck by a bullet. Garros took his Type L fighter into combat with the deflectors in March 1915 and achieved immediate success, shooting down three German aircraft in April, a noteworthy feat at the time.
The bullets that the French used were not to damage the harder steel of the wedges themselves. On 18 April 1915, Garros' deflector-equipped Type L force-landed behind German lines and was captured before he could destroy it. Three two-seat Morane Type L aircraft were the first victims of the first German fighter aircraft. Leutnant Kurt Wintgens, flying the Parabellum machine gun-armed Fokker Eindecker M.5K/MG prototype E.5/15, a copy of the Morane-Saulnier H with a wire-braced welded steel tube fuselage and fitted with the Fokker Stangensteuerung synchronized gun, downed the first on July 1, 1915, followed by two similar victories on July 4 and 15. About 50 Type Ls were delivered to Britain's Royal Flying Corps, which used them as reconnaissance aircraft during 1915, with a further 25 being operated by the Royal Naval Air Service. On 7 June 1915 one of these aircraft, flown by Flight Sub-Lieutenant Reginald Alexander John Warneford of 1 Squadron RNAS intercepted the Deutsches Heer-flown Zeppelin LZ.37, destroying it, the first Zeppelin to be destroyed in the air.
Warneford received the Victoria Cross for this achievement. Cecil Lewis served with the RFC's Squadron Number 3 in 1916 through the Somme offensive, he flew the Type LA "Parasol" operationally, for over three hundred hours and was awarded the Military Cross. Most of that flying was conducted on a single airframe, RFC serial 5133. In his book "Sagittarius Rising" he recalled of the LA: "I had a look over her, the more I saw of her the less I liked her, it was not love at first sight... the elevator was as sensitive as a gold balance. You couldn't leave the machine to its own devices for a moment... the Morane was a death trap... Subsequently I flew, they were all child's play after the Morane... but I did come to love the Morane as I loved no other aeroplane."Three Pfalz A. II's were used by the Ottoman Empire in an attempt to combat the growing threat of the Arab RevoltA Morane-Saulnier "Parasol" was used for the first flight by an airplane across the Andes on April 13, 1918, when the Argentine aviator Luis Candelaria flew from Zapala, Argentina, to Cunco, Chile.
L basic model LA improved L with faired fuselage A. I with Oberursel U.0 engine A. II with Oberursel U. I engine E. III - A Pfalz A. II armed with single synchronised lMG 08 machine gun ArgentinaArgentine Air Force - One aircraft BelgiumBelgian Air Force BrazilBrazilian Army Aviation CzechoslovakiaCzechoslovakian Air Force - One aircraft FinlandFinnish Air Force - Two aircraft FranceFrench Air Force NetherlandsRoyal Netherlands Air Force - One aircraft. PeruPeruvian Air Force PolandPolish Air Force RomaniaRoyal Romanian Air Force Russian EmpireImperial Russian Air Service SwedenSwedish Air Force - One aircraft SwitzerlandSwiss Air Force - One aircraft TurkeyOttoman Air Force - Original and Pfalz A. II aircraft. UkraineUkrainian Air Force - Three aircraft. Soviet UnionSoviet Air Force - ex-Imperial Russian Air Service aircraft. United KingdomRoyal Flying Corps No. 1 Squadron RFC No. 3 Squadron RFC No. 30 Squadron RFC Royal Naval Air Service Data from Aeroplanes of the Royal Flying Corps General characteristics Crew: 2 Length: 6.88 m Wingspan: 11.20 m Height: 3.93 m Wing area: 18.3 m² Empty weight: 393 kg Loaded weight: 677.5 kg Powerplant: 1 × Le Rhône 9C 9-cylinder rotary engine, 60 kW Performance Maximum speed: 125 km/h at
The Morane-Saulnier G was a two-seat sport and racing monoplane produced in France before the First World War. It was a development of the racing monoplanes designed by Léon Morane and Raymond Saulnier after leaving Borel and, like its predecessors, was a wire-braced, shoulder-wing monoplane. Construction was of fabric-covered wood throughout, except for the undercarriage struts which were of steel tube; the type was a sporting success. In April 1913, Roland Garros took second place in the inaugural Schneider Cup in a floatplane version, finishing with a time of 40 minutes 40 seconds. On 26 June, Claude Grahame-White flew another float-equipped example from Paris to London via Le Havre, Boulogne-sur-Mer, Dover, covering some 500 km that day. Between 21 and 28 September the same year, two float-equipped Type Gs competed at the seaplane meeting at San Sebastián, with Lord Carbery winning the short takeoff prize on one, Edmond Audemars winning the maneuverability prize on the other; the following week, Carbery flew his Type G in the Italian Waterplane Contest from Lake Como to Pavia and back, along with two other Type Gs in the field of fifteen competitors, these flown by Garros and Morane.
Garros not only won the Grand Prize in the "general class", but the prizes for best speed and greatest altitude. On 28 September 1913 Roland Garros became the first person to cross the Mediterranean Sea by air, flying from Fréjus in the south of France to Bizerte in Tunisia in a Morane-Saulnier G. In 1914, Russian manufacturer Duks arranged to build the type under licence at their Moscow factory for the Russian Army, the same year, the Turkish military ordered 40 examples. Before these could be delivered, war broke out, the aircraft were impressed into the French Army. To these, the Army soon added an order of 94 aircraft, the British Royal Flying Corps acquired a number, these latter machines purchased from Grahame-White, manufacturing the type in the UK under licence. At the outbreak of war, the type's military value was found to be wanting, the French machines were relegated to training duties. Despite this, a dedicated single-seat fighter version was built in 1915, armed with an 8 mm Hotchkiss machine gun that fired through the propeller arc, the propeller blades being protected by deflector plates.
Only one or two prototypes were built, the type never entered service. Some Type Gs were modified by Morane-Saulnier to have their wings mounted above the fuselage, parasol-fashion, rather than at the fuselage sides; this arrangement was found to offer far better visibility for the pilot, formed the basis for the Morane-Saulnier L. A Type G is preserved at the Museo del Aire. Type GA version with 40 kW Le Rhône engine Type GB version with 60 kW Gnome engine Type WB version for export to Russia with glazed forward fuselage MoS-2 official French government STAe designation for the G Thulin B Licence-built by AB Thulinverken in Sweden Grahame-White Type XIV License built by Claude Grahame-White in the United KingdomVarious versions were given the STAé designation MoS-2, MoS-14, MoS-15, MoS-17, MoS-18 and MoS-19. ArgentinaArgentine Air Force CubaCuban Air Force - One aircraft. FranceAéronautique Militaire French Navy RussiaImperial Russian Air Force Soviet UnionSoviet Air Force - Taken over from the Imperial Russian Air Force.
SpainSpanish Air Force TurkeyOttoman Air Force - 40 ordered, but never delivered. United KingdomRoyal Flying Corps Data from Jane's Fighting Aircraft of World War I, 116General characteristics Crew: one pilot Capacity: one passenger Length: 6.30 m Wingspan: 9.20 m Wing area: 16 m2 Empty weight: 95 kg Gross weight: 370 kg Powerplant: 1 × Gnome, 60 kW Performance Maximum speed: 123 km/h Rate of climb: 1.8 m/s Armament Green, William. The Complete Book of Fighters. Godalming, UK: Colour Library Direct. ISBN 0-86288-220-6. Hartmann, Gérard. "L'incroyable Morane-Saulnier hydro". La Coupe Schneider et hydravions anciens/Dossiers historiques moteurs. Retrieved 2008-11-07; the Illustrated Encyclopedia of Aircraft. London: Aerospace Publishing. "Italian Waterplane Contest". Flight: 1129. 11 October 1913. Retrieved 2008-11-10. Jane's Fighting Aircraft of World War I. London: Studio Editions. 2001. ISBN 0-517-03376-3. "The Latest Morane-Saulnier Monoplane". Flight: 561–64. 24 May 1913. Retrieved 2008-11-07. "The Monaco Meeting".
Flight: 450. 19 April 1913. Retrieved 2008-11-07. "Mr Grahame-Wnite's Seine—Thames Trip". Flight: 749. 5 July 1913. Retrieved 2008-11-07. "Morane-Saulnier type G". EADS website. Retrieved 2008-11-07. Taylor, Michael J. H.. Jane's Encyclopedia of Aviation. London: Studio Editions. ISBN 0-7106-0710-5
The Morane-Saulnier MS.129 and its derivatives in the MS.130 series were a family of military trainer aircraft produced in France in the 1920s. They were conventional, parasol-wing monoplanes with open cockpits in tandem and fixed tailskid undercarriage; the initial version, the MS.129, was produced in small numbers for the Romanian Air Force and civil users, but the major production version was the MS.130, which equipped the French Navy and a number of foreign air arms. The second MS.130 prototype won the 1929 Coupe Michelin, flown by Michel Detroyat with an average speed of 190 km/h. The MS.130 was further developed as the MS.230, at least two MS.130s were rebuilt to this new standard. MS.129 initial production version with Hispano-Suiza 8Ab engine. MS.130 major production version with Salmson 9AB engine. MS.130 Coupe Michelin A single aircraft modified for competing in the Coupe Michelin 1929, which Michel Détroyat won at 190.203 km/h. MS.131 MS.130 converted to use a 230 hp Lorraine 7Me engine MS.132 version with Salmson 7Ac engine for French Navy.
MS.133 version with Gnome-Rhône 5Kc engine. MS.134 conversion of MS.130 with Clerget 9B engineThe MS.135, MS.136, MS.137, MS.138, MS.139 were of a different design derived from the MS.35, not related to the MS.130. France France Aéronavale Aéronautique Militaire Brazil Brazil Brazilian Air Force Varig Belgium Belgium China Guatemala Portugal Portuguese Air Force Romania Turkey Data from The Illustrated Encyclopedia of Aircraft 2554General characteristics Crew: Two and instructor Length: 6.97 m Wingspan: 10.70 m Height: 2.85 m Wing area: 19.7 m2 Empty weight: 793 kg Gross weight: 1,149 kg Powerplant: 1 × Salmson 9Ab, 170 kW Performance Maximum speed: 208 km/h Range: 510 km Service ceiling: 5,000 m Armament Related lists List of Interwar military aircraft The Illustrated Encyclopedia of Aircraft. London: Aerospace Publishing. "The Michelin Cup". Flight: 623. 8 July 1932. Retrieved 2008-11-14. Niccoli, Riccardo. "Atlantic Sentinels: The Portuguese Air Force Since 1912". Air Enthusiast. No. 73. Pp. 20–35.
ISSN 0143-5450. Taylor, Michael J. H.. Jane's Encyclopedia of Aviation. London: Studio Editions. ISBN 0-7106-0710-5
DAHER-SOCATA is a producer of general aviation aircraft propelled by piston engines and turboprops, including business planes, small personal or training aircraft, as well as the production of aircraft structures for other manufacturers such as Airbus, Embraer and Lockheed Martin. The company headquarters is located in Tarbes, France. In March 2015 the company name was again changed to just Daher as part of a rebranding to align the division with its parent company Daher; the history of Socata goes back to 1911. In 1966, Morane-Saulnier changed its name to SOCATA when the company was bought by Sud Aviation to produce small aircraft. In 2000 Socata became a wholly owned subsidiary of EADS. On 27 June 2008, EADS announced its intention to sell a controlling interest in EADS Socata to DAHER. On 3 November 2008, EADS and DAHER announced that they had reached an agreement for DAHER to acquire a 70% of Socata. On 7 January 2009, DAHER confirmed its acquisition of a majority 70% stake in SOCATA. Daher acquired the remaining 30% of SOCATA from Airbus Group in June 2014.
Aircraft being produced by Socata TBM 910/930Aircraft produced by Socata in the past Rallye series ST 10 Diplomate TB 30 Epsilon TB 9 Tampico GT TB 10 Tobago GT TB 200 Tobago XL GT TB 20 Trinidad GT TB 21 Trinidad TC GT TBM 700/850/900 Socata HorizonAircraft that never entered production TB 31 Omega TB 360 Tangara Official website
The Morane-Saulnier T was a bomber aircraft developed in France in 1915 and produced in small numbers during World War I. The Morane-Saulnier T was a large, five-bay biplane of conventional configuration, with unstaggered wings of equal span; the conical rear fuselage and large triangular vertical stabilizer were reminiscent of a scaled-up version of some Morane-Saulnier's smaller designs. The engines were mounted tractor-fashion in streamlined nacelles supported by struts in the interplane gap and the propellers on the Type T were fitted with large spinners; the landing gear consisted of two main units, each of which had two wheels joined by a long axle, plus a tailskid and an auxiliary nosewheel. Three open cockpits in tandem were provided: one in the nose for a gunner, others for the pilot and a second gunner placed further back. Although designed as a bomber, the French Army ordered the type T in 1916 hoping to use it either as a bomber escort or reconnaissance aircraft. Only one example of the Type S was built, while an order was placed for 100 Type T aircraft, although only 60 or so of these were built before production was cancelled.
Morane-Saulnier T company designation for 80 hp Le Rhône 9C powered version MoS-25 official French government STAe designation for the T Data from Jane's Fighting Aircraft of World War IGeneral characteristics Crew: 3 Wingspan: 17.65 m Powerplant: 2 × Le Rhône 9C 9 cylinder air-cooled rotary piston engines, 60 kW each Propellers: 2-bladed fixed pitch propellersPerformance Maximum speed: 156 km/h Service ceiling: 4,500 m Armament Bombs: 640 kg Davilla, Dr. James J.. French Aircraft of the First World War. Mountain View, CA: Flying Machines Press. ISBN 978-1891268090. Passieux, JN. "Morane-Saulnier T". Jn.passieux.free.fr. Paris. Retrieved 27 September 2018


text:
The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
- Tablets, chewable 500 mg
Inhibits helminth-specific enzyme fumarate reductase; suppresses egg or larval production and may inhibit subsequent development of eggs or larvae that are passed in the stool.
Thiabendazole is rapidly absorbed. T max is within 1 to 2 h.
Thiabendazole is almost completely metabolized to the 5-hydroxy form, which appears in the urine as glucuronide or sulfate conjugates.
In 48 h, about 5% of a thiabendazole dose is recovered from feces and 90% from urine.
Indications and Usage
Treatment of strongyloidiasis (threadworm infection), cutaneous larva migrans (creeping eruption), and visceral larva migrans alone or in conjunction with enterobiasis (pinworm). Secondary therapy for uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale ), trichuriasis (whipworm), and ascariasis (large roundworm); alleviation of symptoms of trichinosis during invasive phase.
Dosage and AdministrationAdults at least 150 lb (68 kg)
PO 1.5 g/dose twice daily (max, 3 g/day).Adults and Children 30 to 150 lb (13.6 to 68 kg)
PO 10 mg/lb/dose (22 mg/kg/dose) (max, 3 g/day).Strongyloidiasis, Ascariasis, Uncinariasis, Trichuriasis, Cutaneous larva migrans
Two doses daily for 2 successive days (may repeat for some indications).Trichinosis
Two doses daily for 2 to 4 successive days.Visceral larva migrans
Two doses daily for 7 successive days.
Store at room temperature.
Thiabendazole may increase serum concentrations of theophylline to potentially toxic levels.
Laboratory Test Interactions
None well documented.
Dizziness; fatigue; drowsiness; giddiness; headache; numbness; hyperirritability; seizures; collapse.
Tinnitus; abnormal sensation in eyes; xanthopsia; blurring of vision; drying of mucous membranes; appearance of live ascaris in mouth and nose.
Anorexia; nausea; vomiting; diarrhea; epigastric distress.
Hematuria; enuresis; malodor of urine; crystalluria.
Jaundice; cholestasis; parenchymal liver damage, transient rise in cephalin flocculation and AST.
Hypersensitivity reaction (pruritus, fever, facial flush, chills, conjunctival injection (red eye), angioedema, anaphylaxis, skin rashes, erythema multiforme, lymphadenopathy).
Category C .
Safety and efficacy in children weighing less than 13.6 kg (30 lb) not established.
Mixed infections with Ascaris lumbricoides
Thiabendazole may cause these worms to migrate. Drug should not be used prophylactically.
Anemic, dehydrated, or malnourished patients may need concomitant therapy to reverse these conditions.
Transient visual disturbances, psychic alterations.
- Instruct patient to take medicine with food. No special diets are needed.
- Advise patient that all family members should be treated and that treatment may need to be repeated in 7 days to prevent reinfection.
- Instruct patient to bathe daily and to launder bed linens, clothes, and towels daily. Instruct patient on proper technique for hygiene and hand-washing.
- Advise patient to avoid consuming excessive amounts of caffeine-containing beverages, such as coffee.
- Instruct patient to inform health care provider immediately of any symptoms of hypersensitivity or overdosage.
- Advise patient that drug can cause drowsiness and dizziness and to use caution while driving or performing other tasks requiring mental alertness.
Copyright © 2009 Wolters Kluwer Health.

domain: medical


Care Facility Resident Caught Throwing Rocks, Making Threats
A man who got away from a Fayette County care center over the weekend ended up in jail.
Sheriff's officials received a report that a man walked out of the Prairie View Residential Facility near Fayette around 6:30 PM Saturday. Benjamin Wilson, 25, was found a short time later. He apparently was out in the road, throwing rocks and making threats.
Wilson was taken into custody on a charge of disorderly conduct.
Deputies took Wilson to the Fayette County jail in West Union, where he was held until his initial court appearance.


text: Please be very specific with your suggestions, and avoid large topical subjects such as "education," "air quality" and "healthcare." Try framing the issue as a question. For example: Rather than submitting "air quality in southeast Washington and northeast Oregon," ask "Is the quality of southeast Washington and northeast Oregon's air deteriorating? If so, what impact will that have on the regions quality of life and economic development? What can be done to make the air cleaner?"

domain: geography


text:
203 Users Online
A Detailed Analysis of the Drug Discovery Enzymes Market Based on the Rising Demand for Innovative Solutions in Pharmaceutical Drug Discovery
The global drug discovery enzymes market is forecast to expand at a CAGR of 7.7% and thereby increase from a value of US$1.8 Bn in 2023, to US$3 Bn by the end of 2030.
Drug Discovery Enzymes Market Size (2023E)
Projected Market Value (2030F)
Global Market Growth Rate (CAGR 2023 to 2030)
Historical Market Growth Rate (CAGR 2018 to 2022)
Drug discovery enzymes constitute a specialized class of enzymes integral to the exploration and creation of novel pharmaceutical compounds. These enzymes play a crucial role in specific functions such as protein engineering, screening, optimization, and drug molecule synthesis. Leveraging drug discovery enzymes empowers scientists to enhance the drug development process by expediting chemical reactions, improving efficiency, and augmenting the overall success rate of drug discovery initiatives. Typically sourced from natural origins like microorganisms or plants, these enzymes showcase exceptional catalytic properties, facilitating the generation of intricate drug molecules.
The market for drug discovery enzymes has witnessed significant expansion in recent years, fueled by the increasing need for innovative drugs and advancements in biotechnology. Enzymes play a vital role in the drug discovery journey, serving as effective tools for target identification, lead optimization, and drug synthesis. This market features numerous key players providing an extensive array of enzyme products and services. The continuous rise in research and development investments, coupled with the growing embrace of enzymatic technologies, is anticipated to drive further growth in the drug discovery enzymes market.
Increasing Disease Burden, and Technological Advancements in Enzyme Engineering
The global prevalence of diseases like cancer, cardiovascular disorders, and infectious diseases has been on a consistent rise. Cancer, a leading cause of global mortality, resulted in nearly 10 million deaths in 2020, representing almost one in six deaths. In low- and lower-middle-income countries, infections such as human papillomavirus (HPV), and hepatitis contribute to approximately 30% of cancer cases. Each year, around 400,000 children are diagnosed with cancer, and the most common types vary across countries, with cervical cancer being predominant in 23 nations. This surge in disease incidence has generated a heightened demand for effective therapeutics, propelling the expansion of the drug discovery enzymes market.
The field of drug discovery enzymes has witnessed significant progress due to notable advancements in enzyme engineering techniques. The creation of new enzyme variants featuring improved catalytic properties and stability has played a crucial role in expediting the identification and optimization of potential drug candidates.
Handling and Safety Hazards Associated with Enzymes
The growth of the market is anticipated to be constrained by challenges related to the handling and safety hazards associated with enzymes, as well as heightened susceptibility to temperature and pH variations. Moreover, the market faces hindrances in terms of elevated financial costs and challenges in recruiting and retaining participants, impeding its overall growth. Furthermore, inadequacies in the clinical research workforce, obstacles imposed by drug sponsors, and issues about the globalization of clinical research are potential factors that may negatively impact market expansion.
Lack of Standardization, and Concerns Around IP Rights
The absence of standardization in enzymatic assays and protocols poses a challenge to result in reproducibility and the comparison of data among various research groups. Initiatives to establish standardized protocols and assay formats are in progress but need additional refinement and widespread adoption. In the drug discovery enzymes market, intellectual property rights wield substantial influence. Securing patent protection for novel enzymes and enzyme-related technologies is essential to stimulate innovation and attract investment. Nevertheless, intricate patent landscapes and the expiration of specific patents can influence market dynamics.
Development of Novel Enzyme Variants, and Growing Integration of AI and ML
Ongoing progress in enzyme engineering techniques presents prospects for creating innovative enzyme variants characterized by improved catalytic properties, stability, and substrate specificity. These developments open doors to new applications and enhance the effectiveness of drug discovery procedures. The incorporation of Artificial Intelligence (AI), and machine learning (ML) technologies into drug discovery holds the potential to transform the field significantly. AI and ML algorithms can predict enzyme properties, optimize enzymatic reactions, and devise novel platforms for enzyme-based drug discovery.
Which is the Top Product Type Segment?
Kinases Secure Top Rank for their Vital Role in Signal Transduction Pathways
Kinases, as enzymes, facilitate the transfer of phosphate groups from ATP to target molecules, predominantly proteins. Their pivotal involvement in signal transduction pathways makes them appealing targets for drug discovery, particularly within the oncology sector.
Which Sector is the Most Prominent End User?
Pharma and Biotech Companies Register Notable Demand Generation
The pharmaceutical and biotechnology sector is experiencing rapid growth within the market, driven by the widespread applications of enzymes. Enzymes are utilized for various purposes, including the synthesis of antimicrobials, dynamic kinetic resolution of drugs, production of APIs, enzyme therapy, and amino acid synthesis. The incorporation of enzymes in drug formulations has paved the way for treating conditions like cancer and AIDS, thereby generating significant opportunities in this segment.
Top Regional Markets
North America Takes the Lead with Significantly High Per Capita Healthcare Expenditure
The North American pharmaceutical and biotechnology industries thrive on early adoption of state-of-the-art technology, driven by significant per capita healthcare expenditures and the introduction of groundbreaking enzyme-based drugs. In 2022, U.S. healthcare spending experienced a 4.1 percent growth, reaching a total of $4.5 trillion, equivalent to $13,493 per person. This expenditure constituted 17.3 percent of the nation's Gross Domestic Product. Beyond their role in digestive aids, advancements in enzyme formulation have been instrumental in discovering novel applications for enzymes within the pharmaceutical sector.
Higher Prevalence of Chronic Diseases to Push Asia Pacific
The region is witnessing increased market growth due to the emergence of new enzymes designed to address various chronic illnesses, coupled with heightened development initiatives by major companies. A significant factor contributing to this growth is the prevalence of chronic diseases in the population, with six in ten Americans living with at least one chronic condition such as heart disease, stroke, cancer, or diabetes. These chronic diseases not only represent leading causes of death and disability but also contribute significantly to healthcare costs. Additionally, the region is experiencing rapid expansion, attributed to the availability of highly skilled labor at cost-effective rates and the implementation of environmental regulations in recent years.
The drug discovery enzymes market is anticipated to undergo substantial expansion and change. It is recommended that industry players proactively pursue partnerships and cooperation with other relevant parties, such as technology suppliers, research institutes, and pharmaceutical companies. These collaborations can help with resource optimization, knowledge exchange, and the creation of creative drug discovery solutions. In the market for drug discovery enzymes, staying up to date with technical developments is essential. Businesses should make investments in the integration of robots, automation, artificial intelligence, and machine learning technologies to boost productivity, strengthen data analysis skills, and quicken the drug discovery process.
Several factors, including the Increased disease burden and growing focus on Biopharmaceuticals, all contribute to the dynamic and rapid expansion of the global drug discovery enzymes market. Sigma-Aldrich Co. LLC., Kaneka Corporation, Actelion Pharmaceuticals Ltd, Genesis Biotechnology Group, and Suven Life Sciences Limited are market leaders in the manufacturing sector. The countries of Germany, Japan, China, France, and the United States are significant producers of various goods. The United States has embraced advanced techniques and possesses a well-established infrastructure. Key medications such as Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and others are readily available in the U.S. market.
Several corporations are allocating resources toward expanding their capacity to satisfy the increasing need for advanced technology in the pharmaceutical & biotechnology industries. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products.
Prominent organizations, including Sigma-Aldrich Co. LLC., Kaneka Corporation, and Actelion Pharmaceuticals Ltd, are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the Drug industry. Organizations operating within this sector prioritize rigorous research and development endeavors geared towards creating innovative enzymes, refining enzyme engineering techniques, and broadening applications in drug discovery. Market participants are dedicated to augmenting their product portfolios with advanced features, expanding their geographical reach, and cultivating robust relationships with pharmaceutical companies and research institutions.
To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing distinctive attributes, enhanced precision, and adhering to strict regulatory standards and quality assurance to acquire more customers and gain a competitive edge over their rivals.
New Product Launch
In November 2020, Genesis Therapeutics, and Genentech entered into a collaboration for AI-driven, multi-target drug development. This partnership leverages Genesis' expertise in graph machine learning and drug discovery to identify new drug candidates targeting various therapeutic targets across multiple disease categories.
Market Impact: The efficiency and accuracy of finding new medication candidates will probably be improved by Genesis Therapeutics' expertise in graph machine learning and drug discovery technology. Through the use of cutting-edge AI methods, the collaboration aims to expedite the process of finding new drugs by identifying therapeutic targets more quickly across a range of illness categories. Through the introduction of innovative concepts and an increase in the success rate of drug development campaigns, this partnership has the potential to support the expansion of the drug discovery enzymes market.
In January 2020, Bayer entered into a collaboration with Exscientia, an artificial intelligence-driven drug discovery company. This partnership aims to jointly develop and optimize novel lead structures for potential therapeutic candidates, focusing on the treatment of cardiovascular and oncological diseases.
Market Impact: The drug development process may be sped up by the use of cutting-edge technology like artificial intelligence, which could result in the discovery of enzyme-based solutions with better qualities. Furthermore, the emphasis on creating treatment candidates for cancer and cardiovascular disorders shows a strategic alignment with taking on important health issues. The market for drug discovery enzymes may rise as a result of this partnership's potential to increase the use of these enzymes in the treatment of difficult and prevalent medical disorders.
(Source: Drug Discovery Trends)
2023 to 2030
Historical Data Available for
2018 to 2022
US$ Million for Value
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon request
By Product Type:
The market is anticipated to grow at a CAGR of 7.7% during the projected period.
The drug discovery enzymes market was valued at US$1.8 billion in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Sigma-Aldrich Co. LLC., Kaneka Corporation, Actelion Pharmaceuticals Ltd, Genesis Biotechnology Group, and Suven Life Sciences Limited.
The active Kinases segment is expected to grow at the fastest CAGR during the forecast period.


KUALA LUMPUR, Oct 13 — Former Inspector-General of Police Tan Sri Musa Hassan has doubled down on his remarks after he shared an article from a satirical news website on terrorist Osama Bin Laden and the United States’ Central Intelligence Agency (CIA)
Despite repeated attempts by Twitter users to point out the farcical nature of the article by The Onion, which said the CIA made a posthumous apology to Bin Laden in light of new evidence which cleared him of involvement in the September 11, 2001 attacks on the World Trade Centre in New York City, he remained adamant.
“If the news is not true, the US government must deny it,” he said in an early response.
When others began to mock him, or chastise him for believing in the article which could damage the police’s reputation, Musa replied that it had nothing to do with the Malaysian police.
“If it was not broadcasted then no one would spread it around? Is it a freedom to spread false news or slander? If the answer is yes, it is an illogical freedom,” he said, essentially shifting the blame onto The Onion for writing it to begin with.
“No wonder the world is in such chaos, for allowing such false news,” Musa added.
As more and more Twitter users criticised the former inspector-general, he instead went on a lengthy rant about ‘irresponsible journalism’.
“It is still slander even if one meant to be humourous or joking by saying something untrue. Satire or mockery to open society’s eyes to the truths surrounding us is beneficial.
“People have become too ‘intelligent’ until something like this which is a joke is instead not denied as true. Whatever it is, it should be viewed positively as lately there are many theories from America which cast suspicion on the 9/11 incident,” Musa said.
When told that The Onion’s satire is such that no one can possibly believe its contents at face value, he said this enabled irresponsible journalism.
“Only now do I understand that writing on entertainment or comedy is not a form of journalism.
“Hopefully Onion will provide an explanation on the matter, as displayed,” Musa said.
His responses further incensed Twitter users, some of whom continued to mock his apparent lack of knowledge about The Onion, while others continued in their attempts to inform him.
“What is wrong? Why are you angry when an article which has nothing to do with Malaysia is shared?
“You need to see what is being done by a country that always considered itself able in saving the world from terrorism,” Musa said.


PHILADELPHIA >> It was a familiar game in a familiar gym in an all-too-familiar time of the year for Katie May. The challenge, she said, was approaching the moment as though it was revolutionary.
In doing so, May found her edge. It’s also how she found her teammates with wide-open looks, and how Archbishop Wood found its way into the second round of the PIAA Class 5A bracket.
May led the charge Saturday in Archbishop Wood’s 46-25 win over Springfield in the state tournament opener. The senior had 11 points, six rebounds, four steals, and three assists for the Vikings (19-7), whose visit to Catholic League foe Archbishop Ryan’s gym ended with a lopsided victory.
Archbishop Wood, the reigning 5A state champion, has been here before. So has May.
“It kind of feels like another game for us,” the Northeastern commit said. “But with this being my senior year, every game is a big game. So I’m just trying to enjoy it for as long as I can.”
The champion of District 12, Archbishop Wood turned a close game at intermission into a runaway victory. The Vikings shot 8-for-11 from the field in the third quarter, outscored Springfield, 19-5, and induced six turnovers on defense.
May saved her best for the third quarter. On consecutive trips down the floor, she called for the ball just a step outside the paint. On both possessions, she collected a pass, took two dribbles, and surveyed her surroundings for kickout passes to the wing. She found Kaitlyn Orihel both times; once, for a wide-open 3-pointer, and again for a driving layup.
Those passes, coupled with May’s two buckets in the quarter, helped Archbishop Wood open up what had been a tight game. The Vikings transformed a 19-11 halftime lead into a 22-point advantage with eight minutes remaining.
Depth, said Vikings coach Mike McDonald, helped his team flash different defensive looks against Springfield (21-8). Cougars point guard Alyssa Long saw it differently. Archbishop Wood defenders met Long, Springfield’s primary ballhandler, just across midcourt nearly every possession. The Vikings did not relent. They trapped Long on the sidelines, in the corners, and everywhere in between. When she managed to pass out of the double teams, Long’s teammates would receive similar defensive attention.
“That was probably the biggest problem, getting the ball upcourt,” said Long, who finished with six points and two assists. “They gave us so much pressure in the backcourt that we couldn’t get a play started or a set run.
“It just makes things more difficult, more hectic, more chaotic. It’s frustrating. It doesn’t flow to our offense well and, overall, it takes us out of our game, which is probably what they wanted to do.”
Springfield, the fifth seed out of District 1, did not help its cause, either. Archbishop Wood staged a 12-0 run to open the game, and the Vikings applied constant defensive pressure in the backcourt. That approach led to eight first-half turnovers by Springfield, including six in that tumultuous first quarter. For the game, the Cougars shot 5-for-31 overall and 1-for-11 from 3-point range.
“(Archbishop Wood) created havoc and forced turnovers,” said Springfield coach Ky McNichol. “When you play that kind of defense, you’re throwing a double(-team) every single time. It changed everything we wanted to do.
“Then in the second half, we got things close and we just couldn’t get anything to drop; from the foul line, from anywhere. Nothing would drop.”
Archbishop Wood, led by May, also picked up 11 points, five rebounds, and four assists from Bridget Arcidiacono. Orihel wasn’t far behind, with seven points and five boards.
Now, the Vikings are four wins away from claiming their third consecutive state crown.
“I think we have a culture where we expect to win in games like this, and it’s a big confidence booster for our kids,” said McDonald, the Vikings’ coach. “It’s still a matter of execution and having to knock down shots, and that’s what we did today.”
/ 8 hours ago
WHITEMARSH >> It was only an instant, but the image summed up the match...
/ 9 hours ago
EAST MARLBOROUGH >> You hear high school coaches say all the time that their...
/ 13 hours ago
EAST ROCKHILL >> Souderton Area’s speed controlled the pool and sophomore Kristian Stanczewski simply...
/ 22 hours ago
Lower Merion >> Sometimes, the true characteristic of a team does not come out...
/ 1 day ago
Perkiomen Valley 2, Spring-Ford 1, OT >> Sydney Marasco’s sudden-victory goal in the 93rd...
/ 1 day ago
Phoenixville 1, Pottsgrove 1 >> The Phantoms and Falcons played to a draw in...
/ 1 day ago
Jenna Kirby scored the game-winning goal at the 10:53 mark in the overtime period...
/ 1 day ago
WEST GROVE >> When two unbeaten teams squad off, the end result is usually...


TDK confirmed that it's working on a 200GB Blu-ray disc—that's four times the capacity of the largest first-generation dual-layer Blu-ray blanks that are just about to be released worldwide. TDK already showed a next-generation four-layer Blu-ray disc with 100GB of storage in May of last year.
No target date was given for the release of these larger-capacity discs, but the announcement does remind us of one thing: this Blu-ray format can scale up to some mind-boggling capacities. Impressive. You could back up your entire hard drive on one of these things.
TDK working on 200GB Blu-ray disc [TechDigest]


text:
When Cowboys training camp opens next week in Oxnard, California first round pick Byron Jones will face receiver Dez Bryant for the first time.
The Cowboys, who watched Tyron Smith get a baptism by fire courtesy of DeMarcus Ware in his rookie year and believed it went a long way in helping to mold Smith, are looking forward to it.
Of course, Bryant stayed away from the team all offseason as he waited for a new, long-term contract, and Jones was drafted out of UConn in the first round of the draft in late April.
Connecting you to your favorite North Texas sports teams as well as sports news around the globe.
Bryant tweeted Jones shortly after he was selected that night and probably met and spoke with the rookie on the handful of occasions that the All-Pro receiver made appearances at team workouts, but they’ve yet to line up.
“When you’re playing against the best of the best it can only make you better,” Cowboys executive vice president Stephen Jones said, per the Dallas Morning News. "I’m sure Byron is looking forward to it. I know he had some spirited compete plays with Jason Witten who is one of the best in the business. Now he’s going to get to see Dez live and up front. I’m sure he looks forward to it and it’ll be good for him."

domain: sports


text:
Amanda Loncar is a TV and film actress from the United States. She is remembered for her outstanding performance as Piper in the 2006 Fox Television Series The Loop. In addition, she nearly recovered from stage three brain cancer after two years of treatment in November 2009.
Early Life of Amanda Loncar
The actress was born on February 26, 1982, in Arcata, Humboldt County, California, USA. She is now 37 years old as of 2019. Her nationality is American. Her ethnic background is mixed. Pisces is her zodiac sign. Her father is a specialist, and her mother works as a nurse. She also has two younger siblings, Zack and Lily. In terms of her educational background, she attended High School in Sacramento, California. She then went to The New Actors Workshop.
Who is Amanda Loncar Dating Currently?
She is currently unattached. Previously, from 2006 to 2007, she was involved with Ben McKenzie. McKenzie is also an entertainer from the United States. According to gossip, Ben and Amanda split up because Ben’s sexual orientation was not straight. Furthermore, it is untrue, and Ben is currently married to Morena Baccarin. From 2004 to 2005, she had an unofficial relationship with Gavin Degraw.
Estimated Net Worth of Amanda Loncar
As a result, Amanda has an estimated net worth of $1 million US in 2019 and a salary of around $52k US. An entertainer’s salary ranges from $43K to $69K in the United States. The average salary for a film actor or actress is $52 k US.
Amanda Loncar’s Brain Cancer
The actress had brain cancer. She was in the third stage of mind malignant growth at the time she found out about it. Stage III malignant growth is referred to as a cutting-edge disease. During this time, the tumor may have grown to a specific size or may be made up of multiple tumors. During her treatment, she underwent a number of cerebrum medical procedures, chemotherapy, and radiation treatment. Her specialist was Dr. Keith Black. Amanda survives, and the entire procedure was completed in March 2008. In November 2009, she was completely recovered from arranging three brain cancers after nearly two years of treatment.
Body Measurement of Amanda Loncar
Amanda is 5 feet 4 inches tall. Her weight is 50kg. She has blue eyes and blonde hair. Her measurements are 34-23-34 inches.
Professional Career of Amanda Loncar
Amanda began her career in 2004 as an uncredited extra in the 10-minute short film Flash. In the year 2005, she appeared in TV shows such as Law and Order: Criminal Intent as Carly and CSI: Miami as Whitney. She also appeared in the TV movie Fertile Ground as Whitney. This year, she appeared in two TV shows: The Loop as Piper and the Bedford Diaries.
The actress appeared in a number of films, including Live!, On the Road with Judas, Lions for Lambs, and TV shows such as Grey’s Anatomy, How I Met Your Mother, and It’s a Mall World. As appeared in Chapter 5: TV’s Dressed to Kill arrangement Lipstick Winters did Sasha Winters’ job. She played Suzy in the parody film Still Waiting for Suzy. This film was directed by Jeff Balis and composed by Rob McKittrick and Rob McKittrick. She appeared alongside Rayan Hansen in the TV film Lovelies close by. Rob Greenberg directed the film, which was composed by Chris Sheridan.

domain: celebrity


FCP-X and the Pain of Democratization
Avid editors looking for a bit of shameless gloating will enjoy the latest installment in Kanen (John) Flowers’ podcast “That Post Show” (iTunes). Dormant for some two years, the show has reappeared with a new episode featuring four longtime Final Cut editors talking about FCP-X — and they are not happy. In their view, Apple has turned its back on professionals, creating a program they can’t use to make a living and leaving them with little alternative but to switch to Premiere or Media Composer. Some of the features they mourn: a source monitor, multi-cam editing, bins, windows that can be broken up onto multiple monitors, trim mode (they reserve special scorn for FCP-X’s “precision” trimmer, pointing out that FCP-X is inherently imprecise), the ability to cut from one sequence into another, OMF/AAF export, EDL support. The show was recorded soon after the release and is thus based on the earliest of first impressions, but it makes for some entertaining listening.
There are plenty of serious limitations in FCP-X — but there were huge limitations in FCP1, too. The pain of democratization is always wrenching, and this release of Final Cut will be no different. Every new release, it seems (including the appearance of the first Media Composer), has made editing more accessible and expanded the base of editorial talent. But by seeming to abandon its existing customers, Apple has confronted many editors with a choice they never wanted to make, and forsaking the company that once empowered them, or accepting a program that doesn’t serve their needs. Whatever you think of Avid’s performance over the last decade, new management has been doing its level best to listen to and work with editors.
None of this should cause us to overlook the fact that most of the innovation in FCP-X is focused not on workflow, but on editors and the editing process. Randy Ubillos is nothing if not creative when it comes to the experience of editing, and I, for one, want some of those features now: waveforms that don’t constantly redraw; background saving and rendering (rendering has gotten all the press, but saving will mean more to me); background proxy creation (and the ability to switch from proxy to full-res media with a click); “clip connections” that let you drag music or sound effects with the picture it’s synched to; compound clips that allow you to collapse and uncollapse portions of a sequence; “audition” groups that let you cut more than one option and quickly switch between them within the sequence, and of course, excellent timeline performance with long-GOP media. I understand the mixed reaction to the magnetic timeline, but I’d love to have it as an option.
Short term, FCP users are facing a difficult choice, which is good for Adobe and Avid. But long term, FCP-X represents a new challenge, appealing to a whole new audience of media creators and offering them features that nobody else has. Yet.
For those of you who are thinking about making a switch to Media Composer, I encourage you to take a look at my book Avid Agility (now available in print or for Kindle). If you want to get the most out of Media Composer and do it quickly, it’s your best resource.


Quickly dry your car and give it custom finishing touches with this double-sided cloth.
Plush, absorbent microfiber on one side dries your car quickly, and special checked microfiber on the other side spot buffs and shines to a high gleam.
- First use a Car Wash Mitt and water to remove dirt and road grime from your vehicle’s exterior.
- Next, dry your vehicle to a streak-free shine by quickly rubbing a clean Dry and Buff Car Cloth over the entire exterior surface.
- Reserving your Dry and Buff Car Cloth for use only when drying a clean vehicle will help ensure that particles of dirt and debris can never scratch the paint.
- Do not use on anti-glare coated surfaces.
- Always test in an inconspicuous place first.